14.10
2012. R&D- , . 2012. , , , .
Deloitte Thomson Reuters (Measuring the return from pharmaceutical innovation 2012), , R&D , . 20112012. , , 20102011. , ⠗ . .
2012 . -10 R&D 2011., 70,37 . . Genentech ( Roche), Novartis, Merck&Co., Pfizer, Johnson & Johnson, Sanofi. R&D 2012. Genentech 10,1 . (21% ), Novartis 9,33 . (16,4%), Merck&Co. 8,16 . (17%), Pfizer 8,16 . (13,3%), Johnson & Johnson 7,66 . (11,6%), Sanofi 6,4 . (14,1%).
Citeline, R&D-, 2012., GlaxoSmithKline, Roche, Novartis, Merck&Co., Pfizer, Sanofi. ӠGlaxoSmithKline 2012 . 257 , Pfizer 225, Merck&Co. 223, Novartis 218, Roche (Genentech) 198, Sanofi 178.
2012 . Genentech, Pfizer Sanofi , 1 . Pfizer 5 : Inlyta(), Elelyso ( ), Bosulif(),Xeljanz (), Eliquis(). Genentech Erivedge() Perjeta(), Sanofi Zaltrap() Aubagio(). Evaluate Pharma, Eliquis 2016 . 2,66 ., Xeljanz 1,95 ., Perjeta 1,89 .
, (), Forbes, , , 100 . ( 2012. 12 20082012 .), , ⠗ (innovation premium). ( ) , ( , ).
